Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 4, 2003, Pages 282-285

  Dickens, David S ^a,c   Kozielski, Rafal ^a,d   Leavey, Patrick J ^b   Timmons, Charles ^b   Cripe, Timothy P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^d Children's Hlthcare of Atlanta ^*  (United States)

Author keywords

Celecoxib; Cyclooxygenase 2; Osteosarcoma; Rhabdomyosarcoma

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SURVIVAL RATE; TUMOR BIOPSY; TUMOR PROMOTION;

ADULT; BONE NEOPLASMS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ISOENZYMES; LIFE TABLES; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OHIO; OSTEOSARCOMA; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TEXAS; TREATMENT OUTCOME;

EID: 0242600552     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200304000-00003     Document Type: Article

References (24)

1. Chen AR. High-dose therapy with stem cell rescue for pediatric solid tumors: rationale and results. Pediatr Transplant 1999;3(suppl 1):78-86.
2. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20:2150-6.
3. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
4. Diaz A, Chepenik KP, Kom JH, et al. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 1998;241:222-9.
5. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14.
6. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
7. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
8. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61:303-8.
9. Klimp AH, Hollema H, Kempinga C, et al. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001;61:7305-9.
10. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-8.
11. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
12. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
13. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001;91:1876-81.
14. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-30.
15. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61:4375-81.
16. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
17. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
18. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-37.
19. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11.
20. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
21. Leung KH. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2. Cell Immunol 1989;123:384-95.
22. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 Expression in Pediatric Sarcomas. Pediatr Dev Pathol 2002;5:356-64.
23. Waskewich C, Blumenthal RD, Li H, et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
24. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2: player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.